tbuckley/cabot-search huggingface dataset:
A novel panel to detect microsatellite instability and concordance with clinical reference methods in colorectal cancer patients.
Authors: Bart Claes, Rudi Rossau, Liesbeth Bernaerts, Els Fransen, Diether Lambrechts, Patrick Pauwels, Erwin Sablon, Geert G. Maertens
Journal: Journal of Clinical Oncology (2015)

e22135 Background: Detection of microsatellite instability (MSI) is recommended to identify colorectal cancer (CRC) patients with Lynch syndrome. Current clinical reference methods to detect MSI are immunohistochemistry (IHC) for mismatch repair (MMR) proteins or molecular analysis of markers in the “Bethesda panel”, consisting of DNA repeat regions that are frequently mutated in MSI-high (MSI-H) but not in microsatellite stable (MSS) tumors. Methods: We investigated whether a novel panel of homopolymer repeats (Zhao et al. 2014; eLife 3:e02725) could serve as an alternative method to detect MSI. For this novel panel, repeat length was determined on FFPE DNA by PCR followed by melting curve analysis on CFX96 PCR instruments (Bio-Rad, USA). 70 CRC FFPE samples were analyzed for MSI status using the Bethesda panel markers in the MSI analysis system (Promega, USA; MSI-H cutoff: 3 out of 5 positive markers) or using the novel prototype MSI panel (Biocartis, Belgium; MSI-H cutoff: 2 out of 4 positive markers). A subset of 8 samples was also analyzed by IHC for MLH1, PMS2, MSH2 and MSH6 MMR proteins. Results: For 57 samples with results available on both methods, the overall percent agreement was 98.3% (56/57; 13 samples could not be analysed due to low DNA quality: 4 samples failed for both methods, 7 additional samples for Bethesda and 2 additional samples for the novel MSI panel). The novel MSI panel classified 1 additional sample as MSI-H, which was scored MSS by the Bethesda panel, leading to a positive percent agreement of 96% (24/25) and negative percent agreement of 100% (32/32). For samples of which MSI status was also available by IHC, IHC was 88% (7/8) concordant with both the novel panel and the Bethesda panel. Discordances were due to 1 sample that was MSI-H by both molecular methods but MSS by IHC and 1 other sample that was MSI-H by the novel MSI panel and IHC but MSS by the Bethesda panel. Conclusions: The novel MSI panel showed high concordance with clinical reference methods and detected 1 additional MSI-H sample compared to either the Bethesda panel or IHC in a population of 70 CRC samples. As such, it holds promise for future development of a novel PCR-based diagnostic tool for accurate MSI detection.
HIGH BLOOD PRESSURE ON DISCHARGE FROM ACUTE DECOMPENSATED HEART FAILURE IN PATIENTS WITH TYPE 2 DIABETES IS ASSOCIATED WITH DECREASED 12-MONTH MORTALITY: FINDINGS FROM THE GULF-CARE
Authors: Charbel Abi Khalil, Kadhim Sulaiman, Rajvir Singh, Amin Jayyousi, Nidal Asaad, Khalid Al Habib, Alawi Alsheikh-Ali, Jassim Al Suwaidi
Journal: Journal of the American College of Cardiology (2017)
Molecular Prognosis in Multiple Myeloma: The IFM Experience.
Authors: Olivier Decaux, Florence Magrangeas, Laurence Lode, Catherine Charbonnel, Wilfried Gouraud, Philippe Moreau, Jean-Luc Harousseau, Michel Attal, Regis Bataille, Loic Campion, Herve Avet Loiseau, Stephane Minvielle
Journal: Blood (2006)
OBSTRUCTIVE SLEEP APNEA IN ADULT CONGENITAL HEART DISEASE: WHO IS AT RISK?
Authors: Benjamin Hendrickson, Damilola Olatunji, David Briston, Pamela Goldsmith, Matthew Granger, Trisha Gribble, Krista Kukovec, Renee Schnug, Rami Khayat, Curtis Daniels, Elisa Bradley
Journal: Journal of the American College of Cardiology (2017)
Double-Hit and Double-Expressor Lymphomas Are Not Associated with an Adverse Outcome after Allogeneic Stem Cell Transplantation
Authors: Alex F Herrera, Joo Y. Song, Gabriel K. Griffin, Liana Nikolaenko, Matthew Mei, Victoria Bedell, Paola Dal Cin, Christine Pak, Tracey Stiller, Heather Sun, Edwin P. Alyea, Lihua E Budde, Robert W Chen, Yi-Bin Chen, Wing Chung Chan, Corey S. Cutler, Vincent T. Ho, John Koreth, Amrita Krishnan, Joyce L. Murata-Collins, Sarah Nikiforow, Joycelynne M. Palmer, German A. Pihan, Raju Pillai, Leslie Popplewell, Steven T. Rosen, Tanya Siddiqi, Aliyah R Sohani, Jasmine Zain, Larry W. Kwak, Dennis D Weisenburger, Auayporn P. Nademanee, David M. Weinstock, Robert J. Soiffer, Joseph H. Antin, Young Kim, Scott J Rodig, Stephen J. Forman, Philippe Armand
Journal: Blood (2016)
The impact of optimal (&lt;1cm) surgical debulking on survival at the time of recurrence in patients with uterine leiomyosarcoma (LMS)
Authors: M. A. Martino, K. Patrick, R. Wenham, J. Palmer, A. Cantor, P. Twitty, L. Rajaram, J. Lancaster, M. S. Hoffman
Journal: Journal of Clinical Oncology (2007)

16067 Objective: Uterine leiomyosarcoma (LMS) is an uncommon female malignancy with limited treatment options. To evaluate whether there exists a role for surgery at the time of recurrence, we performed an outcomes analysis from over 25 years of treating LMS at a single institution. Methods: Patients with uterine leiomyosarcoma who presented for treatment at the H. Lee Moffitt Cancer Center from 1981–2005 were identified from the cancer registry database. Patients who underwent surgery (with or without adjuvant treatment) at the time of first recurrence were compared to those patients who did not undergo surgery and were managed medically. Cox regression analysis (multivariate) was used to evaluate whether demographic or pathologic characteristics were associated with survival. Survival curves were estimated using the Kaplan-Meier method and p-values with 95% confidence intervals were generated using the log rank test. Results: Forty-six charts were reviewed to identify forty-one patients with leiomyosarcomas arising from the uterus and treated during 1981–2005. Of the forty-one patients identified, only 7% (N=3) are currently in remission, with a mean follow-up of 40 months from the time of first recurrence. Sixteen patients underwent surgery at the time of first recurrence, with 60% (N=10) of these patients having an optimal cytoreduction (&lt;1cm). On multivariate analysis, post-menopausal status (p=0.011), the presence of tumor necrosis (p=0.038) and high pathologic grade (p=0.056) were significant variables associated with decreased survival. Median survival for optimally cytoreduced patients compared to patients medically managed patients was 55.5 months and 20 months, respectively. A trend towards improved survival in the optimally cytoreduced group was suggested but was not statistically significant (P=0.26) Conclusions: Uterine leiomyosarcoma is a disease with a poor prognosis and a high likelihood of recurrence. We have identified post-menopausal status, tumor necrosis, and pathologic grade as significant predictors of survival. Given the limited treatment options available and with a suggested trend toward improved survival, cytoreductive surgery at the time of recurrence may be worthy of future investigation. No significant financial relationships to disclose.
Caractéristiques clinico-pathologiques et modalités de prise en charge de tous les cas d'adénocarcinomes colorectaux de stade T1 diagnostiqués dans le département du Finistère entre 2009 et 2013
Authors: M Robaszkiewicz, A Auffret-Bourhis, M Cariou, A Billot-Grasset, C Picart, J Jézéquel, F Cholet, JB Nousbaum
Journal: Endoscopy (2017)

Les cancers colorectaux (CCR) envahissant la sous-muqueuse (T1) présentent un risque significatif d'envahissement ganglionnaire et de récidive tumorale. Le traitement des formes précoces de CCR est endoscopique et/ou chirurgical. La résection endoscopique est recommandée pour les cancers à faible risque d'extension ganglionnaire. Une chirurgie complémentaire est préconisée en cas de marges de résection envahies ou en cas de facteurs de risque d'extension ganglionnaire. Le but de notre étude était d'analyser les caractéristiques clinico-pathologiques et les modalités de prise en charge de tous les cas d'adénonocarcinomes colorectaux de stade T1 diagnostiqués dans le Finistère entre 2009 et 2013,
Extracorporeal Photopheresis As Second Line Therapy for Steroid Refractory Acute Gvhd: Retrospective Study of Long-Term Outcomes
Authors: Rohini Radia, Emma Das-Gupta, Guillermo Orti, Donal McLornan, Majid A. Kazmi, Christopher P Fox, Jenny L. Byrne, Nigel H. Russell, Kavita Raj
Journal: Blood (2015)
Decentralized Manufacture of TCR-Alpha/Beta and CD19 Depleted Haploidentical Stem Cell Grafts for Children within a Multicenter Phase I/II Clinical Trial
Authors: Michael Schumm, Matthias K. Eyrich, Markus Wiesneth, Halvard Bönig, Peter J. Lang, Paul G. Schlegel, Roland Meisel, Ansgar S. Schulz, Johann Greil, Peter Bader, Murat Aktas, Philipp Dresing, Sandra Karitzky, Silke Holtkamp, Rupert Handgretinger
Journal: Blood (2016)
Staged induction of HIV-1 glycan–dependent broadly neutralizing antibodies
Authors: Mattia Bonsignori, Edward F. Kreider, Daniela Fera, R. Ryan Meyerhoff, Todd Bradley, Kevin Wiehe, S. Munir Alam, Baptiste Aussedat, William E. Walkowicz, Kwan-Ki Hwang, Kevin O. Saunders, Ruijun Zhang, Morgan A. Gladden, Anthony Monroe, Amit Kumar, Shi-Mao Xia, Melissa Cooper, Mark K. Louder, Krisha McKee, Robert T. Bailer, Brendan W. Pier, Claudia A. Jette, Garnett Kelsoe, Wilton B. Williams, Lynn Morris, John Kappes, Kshitij Wagh, Gift Kamanga, Myron S. Cohen, Peter T. Hraber, David C. Montefiori, Ashley Trama, Hua-Xin Liao, Thomas B. Kepler, M. Anthony Moody, Feng Gao, Samuel J. Danishefsky, John R. Mascola, George M. Shaw, Beatrice H. Hahn, Stephen C. Harrison, Bette T. Korber, Barton F. Haynes
Journal: Science Translational Medicine (2017)

Identification of maturation stages of V3-glycan neutralizing antibodies explains the long duration required for their development.
Gemcitabine and vinorelbine followed by weekly docetaxel in patients with advanced non-small-cell lung cancer
Authors: M. Cobo Dols, E. Villar Chamorro, I. Alés Díaz, S. Gil Calle, J. Alcalde García, V. Gutiérrez Calderón, F. Carabantes, F. Carabantes, Á. Montesa Pino, J. J. Bretón García, M. Benavides Orgaz
Journal: Journal of Clinical Oncology (2006)

17129 Background: This trial was designed to evaluate the efficacy and toxicity of the sequential nonplatinum combination chemotherapy consisting of gemcitabine (GEM)/vinorelbine (VNR) followed by weekly docetaxel (DOC) in patients with advanced non-small-cell lung cancer (NSCLC). Methods: Eligibility criteria: stage IV NSCLC, Performance status ≤2, adequate renal, hepatic and bone marrow function. Treatment: VNR 25 mg/m 2 plus GEM 1000 mg/m 2 , on days 1 and 8 of each 21-day cycle, followed by DOC 36 mg/m 2 weekly until progression or unacceptable toxicity. Results: 21 stage IV patients were enrolled. All patients are evaluable for treatment response and toxicity profile. The mean age of the patients was 63 years (range: 51 to 72) with 18 (86%) males and 3 (14%) females. Histology types: adenocarcinoma in 8 patients (38%), large cell carcinoma in 1 patient (5%) and squamous cell carcinoma in 12 patients (57%). Most of the patients had ECOG PS of 1. 8 patients (38%) did not complete 6 cycles of GEM-VNR. The median number of cycles of GEM-VNR was 4 (range 2–6) Of the 13 patients (61%) who completed 6 cycles of GEM-VNR, all of them went on to receive weekly docetaxel and received at least 3 cycles, with a median number of 8 cycles (range 3–16). The overall response rate was 33%. Respect survival, the minimum follow-up was 6 months (range, 6–25 months). The median survival time (MST) was 7,9 months, and the 1-year survival was 30 %, and the median progression-free survival was 4.7 months. Toxicity was mild, well tolerated and mostly hematologic. In the GEM/VNR cycle, grade 3/4 neutropenia occurred in 14%, two patients with febrile neutropenia. Grade 3 anaemia in 1 patient (5%) and grade 3 thrombocytopenia in 1 patient (5%). Nonhematologic toxicity was also mild: 1 patient with Grade 3 skin toxicity with DOC, 1 patient with grade 3 infection, 2 patients with grade 3 astenia and 1 patient with a mild allergic reaction postchemotherapy treatment with DOC. Conclusions: The sequential triplet nonplatinum chemotherapy consisting of GEM/VNR followed by weekly DOC is active and can be administered safely in advanced NSCLC. Our results are similar with other sequential regimens and did not represent a significant improvement in the treatment of this disease. No significant financial relationships to disclose.
PCSK9 Inhibition to Reduce Cardiovascular Events
Authors: Robin P.F. Dullaart
Journal: New England Journal of Medicine (2017)

Since the discovery in 2003 that gain-of-function mutations in the gene encoding proprotein convertase subtilisin–kexin type 9 (PCSK9) cause autosomal dominant hypercholesterolemia, which was followed by the identification in 2005 of loss-of-function mutations in PCSK9 as a cause of lower low-density lipoprotein (LDL) cholesterol levels, interest in the PCSK9 pathway has exploded. PCSK9 is a secreted serine protease that binds to the extracellular domain of the LDL receptor and targets the LDL receptor to the lysosomal compartment for degradation.1 Consequently, PCSK9 prevents recycling of the LDL receptor to the cell surface, thereby attenuating LDL clearance. PCSK9 is present in human . . .
CANT1 lncRNA Triggers Efficient Therapeutic Efficacy by Correcting Aberrant lncing Cascade in Malignant Uveal Melanoma
Authors: Yue Xing, Xuyang Wen, Xia Ding, Jiayan Fan, Peiwei Chai, Renbing Jia, Shengfang Ge, Guanxiang Qian, He Zhang, Xianqun Fan
Journal: Molecular Therapy (2017)

Uveal melanoma (UM) is an intraocular malignant tumor with a high mortality rate. Recent studies have shown the functions of long non-coding RNAs (lncRNAs) in tumorigenesis; thus, targeting tumor-specific lncRNA abnormalities has become an attractive approach for developing therapeutics to treat uveal melanoma. In this study, we identified a novel nuclear CANT1 lncRNA (CASC15-New-Transcript 1) that acts as a necessary UM suppressor. CANT1 significantly reduced tumor metastatic capacity and tumor formation, either in cell culture or in animals harboring tumor xenograft. Intriguingly, XIST lncRNA serves as a potential target of CANT1, and JPX or FTX lncRNA subsequently serves as a contextual hinge to activate a novel CANT1-JPX/FTX-XIST long non-coding (lncing) pathway in UM. Moreover, CANT1 triggers the expression of JPX and FTX by directly binding to their promoters and promoting H3K4 methylation. These observations delineate a novel lncing cascade in which lncRNAs directly build a lncing cascade without coding genes that aims to modulate UM tumorigenesis, thereby specifying a novel "lncing-cascade renewal" anti-tumor therapeutic strategy by correcting aberrant lncing cascade in uveal melanoma.
PRO-INFLAMMATORY INTERLEUKIN-1 GENOTYPES AFFECT THE ASSOCIATION OF C-REACTIVE PROTEIN FOR ANGIOGRAPHICALLY DETERMINEDCORONARY ARTERY DISEASE AND CARDIOVASCULAR EVENTS
Authors: Aris Bechlioulis, Katerina K. Naka, Lynn Doucette-Stamm, Leon Wilkins, Aikaterini Marini, Sophia Giannitsi, John Rogus, Kenneth Kornman, Joseph L. Witztum, Sotirios Tsimikas, Lampros K. Michalis
Journal: Journal of the American College of Cardiology (2017)
CD44 is a key player in non-alcoholic steatohepatitis
Authors: Stéphanie Patouraux, Déborah Rousseau, Stéphanie Bonnafous, Cynthia Lebeaupin, Carmelo Luci, Clémence M. Canivet, Anne-Sophie Schneck, Adeline Bertola, Marie-Christine Saint-Paul, Antonio Iannelli, Jean Gugenheim, Rodolphe Anty, Albert Tran, Béatrice Bailly-Maitre, Philippe Gual
Journal: Journal of Hepatology (2017)
EFFECT OF BIVALIRUDIN VERSUS UNFRACTIONATED HEPARIN IN TRANSCATHETER AORTIC VALVE REPLACEMENT WITH SELF-EXPANDING VALVES: FROM THE BRAVO-3 RANDOMIZED TRIAL
Authors: Jaya Chandrasekhar, Axel Linke, Christian Hengstenberg, Serdar Farhan, Christophe Tron, Andreas Fach, Stephan Windecker, Raban Jeger, Gennaro Sardella, John Webb, Ulrich Schäfer, Thierry Lefevre, Christian Kupatt, Didier Tchetche, Nicolas Dumonteil, Antonio Colombo, Efthymios Deliargyris, Usman Baber, Roxana Mehran, Prodromos Anthopoulos, George Dangas
Journal: Journal of the American College of Cardiology (2017)
MULTI-FETAL GESTATION, BREASTFEEDING, DELIVERY METHOD AND MYOCARDIAL RECOVERY IN PERIPARTUM CARDIOMYOPATHY: RESULTS FROM THE MULTICENTER IPAC STUDY
Authors: Amy Marino, Agnes Koczo, Arun Jeyabalan, Uri Elkayam, Leslie Cooper, James Fett, Dennis McNamara
Journal: Journal of the American College of Cardiology (2017)
A dose-finding study of nanoparticle albumin-bound paclitaxel plus cisplatin in patients with metastatic nasophyngeal carcinomas.
Authors: Li Zhang, Wenhua Liang, Yan Huang, Liping Zhao, Hongyun Zhao, Xuan Wu, Tao Qin
Journal: Journal of Clinical Oncology (2014)

6049 Background: Nanoparticle albumin-bound paclitaxel (Abraxane, ABX), is a novel formulation of paclitaxel that has proved superior efficacy compared with conventional paclitaxel in the treatment of several metastatic cancers. We undertook this trial to determine the optimal dose and to preliminarily aseess efficacy of ABX plus cisplatin (DDP) in nasopharyngeal carcinoma (NPC). Methods: This was an open-label, nonrandomized study. Patients with metastatic NPC who were previously untreated or failed the standard treatment (radiochemotherapy or first-line chemotherapy) were enrolled sequentially into three cohorts (23 patients/cohort, N=69) to receive DDP 75 mg/m2 q3w plus ABX 260mg/m2 q3w (cohort 1), or 140mg/m2 d1, 8 q3w (cohort 2) or weekly ABX 100mg/m2(cohort 3), respectively. Recruitment of any cohort would be deceased if more than one third of patients experienced dose-limiting toxicities (DLTs). Results: All clinical features were balanced among cohorts, including sex, age, histology, proportion of patients with different previous treatments, etc. All cohorts completed recruitment since DLT occured only in one case from cohort 1 and cohort 3 repspetively. The most common grade 3-4 adverse events were neutropenia (50.9%), leukocytopenia (43.6%), anemia (10.9%), fatigue (5.5%) and vomitting (5.5%). The proportion of patients experienced grade 3-4 toxicity is 65.5%, not differing in each cohort (cohort 1, 63.6%; cohort 2, 61.1%; cohort 3, 73.3%; P=0.74). The objecive response rates (ORR) were similar among all cohorts (70.0%, 66.7%, 66.7%, P=0.97). Notably, we observed that patients who had received not any prior chemotherapy (23.6%) had a significantly higher ORR than those who had ever experienced (100% vs. 56.8%, P=0.004), without difference in grade 3-4 toxicity (P=0.314). Conclusions: ABX-DDP is a safe and efficacious regimen for advanced NPC patients. ABX 260mg/m2 q3w, 140mg/m2 d1, 8 q3w or weekly ABX 100mg/m2 showed equivalent response and toxicity. Taking convenience into consideration, we determined ABX 260mg/m2 q3w as the standard dosage in the upcoming phase III randomized controlled trial. Clinical trial information: NCT01735409.
Phase I study of cetuximab, intensity-modulated radiotherapy (C-IMRT), and intratumoral EGFR antisense (AS) DNA in patients with locally advanced head and neck cancer (HNC).
Authors: Julie E. Bauman, Umamaheswar Duvvuri, William E. Gooding, David Andrew Clump, Brian J Karlovits, Ahmad Mouhamad Wehbe, Frank R. Miller, Jonas Talmadge Johnson, Robert L. Ferris, Seungwon Kim, Dwight Earl Heron, James Ohr, Jennifer R. Grandis, Athanassios Argiris
Journal: Journal of Clinical Oncology (2015)

6074 Background: Epidermal growth factor receptor (EGFR) is a validated therapeutic target in HNC. The combination of C-IMRT is a standard for locally advanced HNC; however, failure of locoregional control (LRC) remains the primary cause of cancer-related death. Intratumoral injection of EGFR-AS DNA oligonucleotide was safe and associated with promising lesional response in a phase I study. We conducted a phase I trial to evaluate the safety of C-IMRT and EGFR-AS DNA injections in patients with locally advanced HNC. Methods: Eligible patients had Stage IVa-IVc HNC, ECOG 0-2, no prior RT, and a measurable lesion accessible for repeated injection. Treatment course was 9 wks. C was loaded wk 1 then administered 250 mg/m2/wk for 8 wks. EGFR-AS DNA (11.92mg/1.78mL; no dose modifications) was injected weekly into the selected lesion starting wk 1 until complete response (CR) or a maximum of 7 injections. IMRT (70 Gy; 2 Gy/fraction) was delivered wks 3-9. Biopsies of injected lesions were obtained at baseline and after 2 injections. The primary endpoint was safety; a ≥ 20% rate of grade 3/4 adverse events (AEs) attributable to EGFR-AS DNA was considered unsafe. EGFR signaling in paired biopsies was evaluated by reverse phase protein array (RPPA). Results: Between Apr 2013 and June 2014, 6 patients (4 male; 2 female) were treated. Stage: IVa (4); IVc (2). Primary site: oropharynx (4; HPV+/HPV-/HPVunk 1/1/2); hypopharynx (1); oral tongue (1). Lesion selected for injection: lymph node (LN; 2); oropharynx (3); oral tongue (1). No grade ≥ 2 AEs were attributed to EGFR-AS DNA; 2 of 6 reported grade 1 injection site pain. Expected rates of acneiform rash, RT dermatitis, and mucositis were observed. All patients completed IMRT and 8-9 doses of C. Best lesional response was CR (4), partial response (1), or progression (1). A patient with T2N2cM1 hypopharynx primary had CR in the injected 5 cm LN but only PR in a contralateral 1.5 cm non-injected LN. RPPA results will be presented. Conclusions: The combination of C-IMRT plus EGFR-AS DNA injections was well tolerated. The lesional response pattern is intriguing. A phase II efficacy trial evaluating LRC as the primary endpoint is planned. Clinical trial information: NCT00903461.
ATHEROSCLEROTIC PLAQUE MORPHOLOGY IN RESPONSE TO HIGH INTENSITY LIPID LOWERING THERAPY BY MULTIMODALITY IMAGING AMONG WOMEN AND MEN: A YELLOW-II SUB-STUDY
Authors: Samit Bhatheja, Kipp Johnson, Yuliya Vengrenyuk, Shameer Khader, Takahiro Yoshimura, Glicksberg Benjamin, Akiko Maehara, Meerarani Purushothaman, Milind Mahajan, Pedro Moreno, Roxana Mehran, Usman Baber, Joel Dudley, Jagat Narula, Samin Sharma, Annapoorna Kini
Journal: Journal of the American College of Cardiology (2017)
T315I Mutation INCREASES the GENOMIC Instability and the Mutator Phenotype IN BCR-ABL-Expressing LEUKEMIC CELLS.
Authors: Djamel Aggoune, Angelina Bertrand, Marie Laure Bonnet, Amelie Le Corf, Sandrine Girerd, Fatima Dkhissi, Nathalie Sorel, Jean-Claude Chomel, Annelise Bennaceur-Griscelli, Ali G. Turhan
Journal: Blood (2010)
The Impact of Different Pre-Transplant Regimens Including Novel Agents On Peripheral Blood Mobilization, Harvest, Response and Survival in Patients Undergoing ASCT for Multiple Myeloma. A Single-Center Experience in 210 Patients.
Authors: Evangelos Eleutherakis-Papaiakovou, Dimitrios Christoulas, Magdalini Migkou, Maria Gavriatopoulou, Maria Roussou, Despina Mparmparoussi, Charis Matsouka, Efstathios Manios, Eleni Efstathiou, Efstathios Kastritis, Evangelos Terpos, Meletios A. Dimopoulos, Christos Papadimitriou
Journal: Blood (2009)
Outcome Comparison of Lymphoma and Myeloma Patients after Autologous Stem Cell Transplantation (ASCT) with Peripheral Blood Stem Cell Mobilization Between Plerixafor (P) Mobilized in Poor Mobilizer Patients and Non-Plerixafor Mobilized Patients
Authors: Shahbaz A. Malik, Saul Yanovich, Aaron P. Rapoport, Ashraf Z Badros, Nancy M. Hardy, Mehmet H. Kocoglu, Alison Duffy, Kathleen Ruehle, Jennifer Nishioka, Olga Goloubeva, Jean Yared
Journal: Blood (2015)